Sotrovimab or Xevudy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to emergency authorization of COVID-19 monoclonal antibodies, high hospitalization risk during early pandemic phases, rapid deployment of antibody therapies, government procurement of antiviral treatments, expansion of infusion-based treatment infrastructure.

The growth in the forecast period can be attributed to evolution of variant-resistant antibody therapies, growing focus on preparedness for future pandemics, increased investment in antiviral biologics, expansion of outpatient infusion services, integration of monoclonal antibodies into standard care protocols. Major trends in the forecast period include increasing use of monoclonal antibody therapies, rising focus on early-stage viral treatment, expansion of targeted antiviral biologics, growing emphasis on high-risk patient protection, enhanced development of pandemic-response therapeutics.

The rising prevalence of COVID-19 cases is expected to drive the growth of the Sotrovimab (Xevudy) market. COVID-19, caused by the SARS-CoV-2 virus, spreads through respiratory droplets and can lead to symptoms ranging from mild fever to severe respiratory complications. Despite vaccines and hygiene measures, COVID-19 cases continue to rise due to factors such as emerging variants, waning immunity, relaxed public health measures, seasonal indoor gatherings, and uneven vaccine coverage. Sotrovimab (Xevudy) helps high-risk patients by neutralizing the virus early, reducing the likelihood of severe outcomes like hospitalization or death. For example, in March 2023, the UK Office for National Statistics reported that approximately 1.9 million people in the UK (2.9% of the population) had experienced COVID-19, with 69% reporting symptoms persisting for over a year and 41% for over two years. Therefore, the increasing prevalence of COVID-19 is driving the Sotrovimab (Xevudy) market.

Rising healthcare investments are also expected to propel the Sotrovimab (Xevudy) market. Healthcare investments encompass spending on medical treatments, hospital care, and medications, driven by an aging population, growing healthcare needs, technological advancements, and rising healthcare costs. Increased investments support Sotrovimab (Xevudy) by funding research and development, expanding production, and improving access for high-risk patients through distribution networks and partnerships. For instance, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, accelerating from a 0.9% growth in 2022. Therefore, rising healthcare investments are boosting the Sotrovimab (Xevudy) market.

A key development in the Sotrovimab (Xevudy) market is the strategic collaboration between Vir Biotechnology, a U.S.-based biotech company, and GlaxoSmithKline (GSK), a UK-based pharmaceutical company. In February 2023, the companies updated their agreement to strengthen joint efforts in the development, manufacturing, and commercialization of Sotrovimab and VIR-7832. This collaboration reinforces their commitment to advancing monoclonal antibody programs and ensuring broader patient access to these therapies.

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sotrovimab or xevudy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the sotrovimab or xevudy market by increasing costs of imported biologic manufacturing inputs, monoclonal antibody production equipment, sterile fill-finish components, and cold-chain distribution systems. Healthcare systems in North America and Europe are most affected due to reliance on imported biologics infrastructure, while global distribution programs face elevated logistics expenses. These tariffs are increasing treatment delivery costs and limiting rapid scalability. However, they are also encouraging regional biologics manufacturing, localized supply chains, and expanded domestic capabilities for rapid-response antiviral therapies.

The sotrovimab or xevudy market research report is one of a series of new reports that provides sotrovimab or xevudy market statistics, including sotrovimab or xevudy industry global market size, regional shares, competitors with a sotrovimab or xevudy market share, detailed sotrovimab or xevudy market segments, market trends and opportunities, and any further data you may need to thrive in the sotrovimab or xevudy industry. This sotrovimab or xevudy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sotrovimab (Xevudy) is a monoclonal antibody therapy developed for the treatment of COVID-19. It targets the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used to treat mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, providing an effective option during early-stage infections.

The primary indications for Sotrovimab (Xevudy) are early treatment of COVID-19 and post-exposure prophylaxis. Early treatment involves administering the therapy soon after diagnosis to reduce symptom severity, prevent complications, and lower the risk of hospitalization, especially in high-risk individuals. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by pediatric, adult, and geriatric patients.

The sotrovimab or xevudy market consists of sales of pre-filled syringes and infusion kits. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.